MOSCOW (MRC) -- Inovyn has announced intention to undertake major investment to convert its mercury chlorine cellroom at Stenungsund (Sweden) to membrane technology, said the producer on its site.
Initial design and feasibility studies for the conversion project are under way, with targeted completion of the project by the end of 2017.
Converting the chlorine plant at Stenungsund to the most modern membrane technology forms part of Inovyn’s wider Chlorine Strategy. Through this strategy the company is already well advanced on the expansion of its membrane chlorine cellroom at Antwerp/Lillo (Belgium), which is due to come on line in Q4 2016.
The company has also previously announced a major investment in a large scale potassium hydroxide (KOH) production facility, also at Lillo, which is expected to be on line in late 2017.
Once completed, these projects will complement INOVYN’s existing high quality membrane based production portfolio across Europe, with assets in Belgium, France, Germany, Italy, Norway and the UK.
Comments Jean-Michel Mesland, Operations Director for Inovyn: "Our project at Stenungsund is another major investment by INOVYN that will underpin the sustainability and competitiveness of our business in the long term.
"This and other investments we are making across our European asset base will deliver our commitment to phase out mercury cellroom production in accordance with European regulations.
As MRC reported previously, in early April 2016, Solvay and Ineos agreed to end their Inovyn chlorvinyls joint venture earlier than originally announced. Solvay will receive a final payment of EUR335 million (USD381.3 million) and Ineos will become the sole owner of Inovyn on the completion of the transaction, which is expected in the second half of 2016. The partners formed Inovyn in mid-2015 and announced then that Solvay would exit the jv in July 2018.
Headquartered in London, INOVYN has pro-forma sales of more than EUR3 billion, with 4,300 employees and assets across 14 sites in Belgium, France, Germany, Italy, Norway, Spain, Sweden and the UK. Governance of the Joint Venture is equally split between the partners.
MRC